Jefferies Financial Group Inc. Purchases New Position in Establishment Labs Holdings Inc. $ESTA

Jefferies Financial Group Inc. purchased a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,739 shares of the company’s stock, valued at approximately $750,000.

Several other institutional investors and hedge funds have also bought and sold shares of ESTA. Nantahala Capital Management LLC boosted its position in Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after acquiring an additional 197,962 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Establishment Labs during the 2nd quarter worth approximately $135,752,000. Bamco Inc. NY raised its position in shares of Establishment Labs by 21.5% in the 2nd quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock worth $38,761,000 after acquiring an additional 160,755 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new position in shares of Establishment Labs in the 2nd quarter valued at approximately $61,273,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $70.64 on Monday. The company has a 50 day simple moving average of $85.00 and a two-hundred day simple moving average of $74.94. Establishment Labs Holdings Inc. has a fifty-two week low of $36.53 and a fifty-two week high of $97.59. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -53.92 and a beta of 1.07. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The business’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) earnings per share. Analysts expect that Establishment Labs Holdings Inc. will post -1.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ESTA. Mizuho lifted their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a report on Thursday, August 13th. JPMorgan Chase & Co. raised their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a report on Thursday, August 6th. Finally, TD Cowen upped their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.